PathGroup Selected as Early Access Partner for Launch of Illumina’s Sequencing-Based COVID-19 Diagnostic Test

NASHVILLE, Tenn. – (June 23, 2020) – PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, today announced that the company has been selected as an early access partner for the launch of Illumina’s new sequencing-based COVID-19 test, COVIDSeq™. COVIDSeq accommodates more than 3,000 test samples per run, allowing for a substantial increase in testing capacity.

Illumina, a global leader in sequencing technologies, received the first Emergency Use Authorization from the U.S. Food and Drug Administration for a sequencing-based test on June 9, 2020. COVIDSeq is being rolled out via a limited number of early access sites around the world including PathGroup’s comprehensive 140,000 square foot Nashville-area laboratory.

Click Here to read more.

PathGroup Announces New COVID-19 Testing Option

NASHVILLE, Tenn. – (June 1, 2020) – PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, today announced the availability of a new, minimally-invasive nasal swab collection option as a part of its comprehensive SARS-CoV-2 (COVID-19) testing program.

Many current molecular diagnostic COVID-19 tests rely on a nasopharyngeal (NP) swab, which can cause discomfort for patients during the collection process. The new nasal swab collection option is more comfortable for patients and easier for healthcare providers to administer.

Click here for more information.

Test Available: SARS-CoV-2 (COVID-19) Antibody

Effective May 27, 2020, PathGroup is pleased to announce the availability of a new serologic test for human antibodies to SARS-Cov-2, the viral pathogen associated with COVID-19 (PathGroup Test Code: COVIDAB). On May 3, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Roche Elecsys® SARS-CoV-2 antibody test. The test is for the qualitative detection of total antibodies (including IgG, IgA and IgM) to SARS-CoV-2 in serum from individuals with prior COVID-19 infection. This test may aid in identification of patients with an adaptive immune response to SARS‑CoV‑2, indicating recent or prior infection to the SARS-CoV-2 virus.

Click Here to for more information.

Test Available: Coronavirus Disease 2019 (COVID-19)

Effective March 16, 2020, PathGroup will begin to offer testing for Coronavirus Disease 2019 (COVID-19).  This test is to be ordered only for individuals who meet the Centers for Disease Control and Prevention (CDC) Coronavirus Disease 2019 (COVID-19) clinical and/or epidemiological criteria for testing.  Because this criteria may change as more is learned about the virus, please refer directly to the CDC website for the most up-to-date patient testing criteria: https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html

 

Click here for more information.

It’s Spring Allergy Season!

More than 50 million Americans suffer from allergies every year making allergies the sixth leading cause of chronic illness in the United States. Allergies are a common, yet overlooked, disease and the most common health issue that affects children in the U.S. An estimated 4.2 million children in the U.S. have a food allergy to things like peanuts, eggs, milk, wheat, tree nuts, fish and shellfish.

Click here to learn more!